Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis

Abstract

Serum IL-17 levels and IL-17 mRNA expression have been reported to be higher in psoriatic skin than normal skin. There are very limited data in the literature about difference in the levels of this cytokine in various clinical disease subtypes. We aimed to evaluate whether there is a difference in the level of this cytokine according to clinical subtypes of psoriasis. 70 psoriasis patients (30 plaque psoriasis, 20 guttate psoriasis, and 20 pustular psoriasis) and 50 age- and sex-matched healthy volunteers were included in the study. Serum IL-17 levels were determined by ELISA. Skin biopsies obtained from lesions and non-lesional skin area of 12 patients and healthy individuals (n = 5) were analyzed by quantitative PCR (qPCR) to measure the mRNA levels of IL-17. Statistically, the serum IL-17 levels did not exhibit any difference between the patients and control groups. However, analysis of each subgroup revealed that the IL-17 levels were significantly higher in pustular psoriasis group (10.09 ± 12.6 pg/ml) than controls (4.4 ± 4.1 pg/ml) (p = 0.02). In addition, the IL-17 levels of plaque psoriasis patients with PASI score ≥10 (11.30 ± 6.0 pg/ml) were significantly higher than that of patients with PASI score <10 (3.39 ± 2.6 pg/ml) and controls (p < 0.001). The Pearson correlation analysis showed a positive correlation between the serum IL-17 levels and PASI. Lesional skin samples of psoriasis patients showed significantly higher levels of IL-17 mRNA compared with perilesional skin samples (p = 0.017). Also, in the pustular psoriasis, IL-17 mRNA levels were found to be distinctively high in comparison with other clinical subtypes and healthy controls. Our results indicate that IL-17 and Th17 cells have an important role in pustular psoriasis and severe psoriasis.

Interleukin 17 Drives Vascular Inflammation, Endothelial Dysfunction, and Arterial Hypertension in Psoriasis-Like Skin Disease

“…This is comparable to psoriasis patients, where a positive correlation between the psoriasis area and severity index score and the serum IL-17 level has been described. 26,27 Elevated IL-17A serum levels have also been reported for the imiquimod-induced psoriasis-like skin disease (≈20-40 pg/ mL in IMQ-treated wildtype mice, barely detectable in control mice), 36 although less in comparison to the K14IL-17A ind/+ mice, which can be explained by the smaller area of affected skin. The elevated IL-17A levels in the serum of the K14IL-17A ind/+ mice were accompanied by increased numbers of CD11b + cells-mostly neutrophil granulocytes-in the blood (Figure 2A-2C).…”

“…26 A positive correlation between the psoriasis area and severity index score and the serum IL-17 level in psoriasis vulgaris was described. 27 IL-6 serum levels were increased in the K14IL-17A ind/+ mice ( Figure ID in the online-only Data Supplement), and TNF-α was elevated by trend in the serum and in the skin ( Figure IIIA and IIIB in the online-only Data Supplement). These cytokines have been described to be elevated Figure 3A) and by higher levels of 3-nitrotyrosine in intima and the media ( Figure 3B) compatible with increased formation of the nitric oxide (NO·)/O 2 · − reaction product peroxynitrite (ONOO − ).…”

Reliability and validity of internalized stigmatization scale in psoriasis

“…Bazı hastalarda eklemleri etkileyebilir. Psoriasis hastalarının bir bölümünde metabolik sendrom başta olmak üzere ek hastalıklara da rastlanabilir 1 . Psoriasis dışarıdan fark edilebilen diğer hastalıklarda olduğu gibi bireyi başkalarından farklı kılan, yani stigmatize eden, diğer bir tanımla damgalayan özelliğe sahiptir.…”

Opções Terapêuticas Emergentes no Tratamento da Psoríase em Placas na Forma Moderada a Grave

“…Os níveis de linfócitos T CD4+ com os seus subtipos, em especial os linfócitos Th17, estão muito elevados na pele dos doentes com psoríase. [24][25][26][27][28] Além destes mediadores, as células dendríticas mielóides também afetam queratinócitos e a vascularização da pele, através da produção da IL-20 (moduladora da função dos queratinócitos, ao Revista SPDV 74(3) estimular a sua proliferação) e do óxido nítrico (agente vasodilatador) (não representados).…”

“…[25][26][27][28]32 O bloqueio da IL-17A parece ser uma abordagem sustentável para o tratamento desta doença. 36,71 Esta citocina participa também na resposta imune adaptativa contra infeções bacterianas e fúngicas, através do recrutamento de células inflamatórias para locais de infeção.…”